Literature DB >> 11994489

Inflammatory microcrystals alter the functional phenotype of human osteoblast-like cells in vitro: synergism with IL-1 to overexpress cyclooxygenase-2.

Line Bouchard1, Rinaldo de Médicis, André Lussier, Paul H Naccache, Patrice E Poubelle.   

Abstract

Chronic crystal-associated arthropathies such as gout and pseudogout can lead to local bone destruction. Because osteoblasts, which orchestrate bone remodeling via soluble factors and cell-to-cell interactions, have been described in contact with microcrystals, particularly in uratic foci of gout, we hypothesized that microcrystals of monosodium urate monohydrate (MSUM) and of calcium pyrophosphate dihydrate (CPPD) could alter osteoblastic functions. MSUM and CPPD adhered to human osteoblastic cells (hOB) in vitro and were partly phagocytized as shown by scanning electron microscopy. MSUM and CPPD dose-dependently stimulated the production of PGE(2) in hOB as assessed by enzyme immunoassay, a response that was synergistically enhanced in the presence of IL-1. The mechanism of this synergism was, at least in part, at the level of the expression of cyclooxygenase-2 as evaluated by immunoblot analysis. MSUM and CPPD also stimulated the expression of IL-6 and IL-8 and reduced the 1,25-dihydroxyvitamin D(3)-induced activity of alkaline phosphatase and osteocalcin in hOB (with no synergism with IL-1). MSUM- or CPPD-stimulated expression of IL-6 in hOB pretreated with the selective cyclooxygenase-2 inhibitor NS-398 was increased, unlike that induced by IL-1 alone which was partially reduced. MSUM-, CPPD- or IL-1-induced expression of IL-8 was unchanged by pretreating hOB with NS-398. These results suggest that inflammatory microcrystals alter the normal phenotype of hOB, redirecting them toward reduced bone formation and amplified osteoblast-mediated bone resorption, abnormalities that could play a role in the bone destruction associated with chronic crystal-induced arthritis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994489     DOI: 10.4049/jimmunol.168.10.5310

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Do the radiographic features of joint destruction in tophaceous gout imply a different pathophysiology to that of rheumatoid and psoriatic arthritis?

Authors:  Regan Arendse; Ayanda Gcelu; Christiaan Scott; Peter Beighton; Asgar Kalla
Journal:  Clin Rheumatol       Date:  2010-06-16       Impact factor: 2.980

2.  Whole-body MRI in the childhood form of hypophosphatasia.

Authors:  C Beck; H Morbach; C Wirth; M Beer; H J Girschick
Journal:  Rheumatol Int       Date:  2010-04-10       Impact factor: 2.631

Review 3.  Mechanisms of joint damage in gout: evidence from cellular and imaging studies.

Authors:  Fiona M McQueen; Ashika Chhana; Nicola Dalbeth
Journal:  Nat Rev Rheumatol       Date:  2012-01-10       Impact factor: 20.543

4.  Serum urate levels and the risk of hip fractures: data from the Cardiovascular Health Study.

Authors:  Tapan Mehta; Petra Bůžková; Mark J Sarnak; Michel Chonchol; Jane A Cauley; Erin Wallace; Howard A Fink; John Robbins; Diana Jalal
Journal:  Metabolism       Date:  2014-11-21       Impact factor: 8.694

Review 5.  How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases?

Authors:  C Beck; H Morbach; P Richl; M Stenzel; H J Girschick
Journal:  Rheumatol Int       Date:  2008-09-28       Impact factor: 2.631

Review 6.  Persisting eicosanoid pathways in rheumatic diseases.

Authors:  Marina Korotkova; Per-Johan Jakobsson
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

7.  NLRP3-Inflammasome Activating DAMPs Stimulate an Inflammatory Response in Glia in the Absence of Priming Which Contributes to Brain Inflammation after Injury.

Authors:  Catherine Diane Savage; Gloria Lopez-Castejon; Adam Denes; David Brough
Journal:  Front Immunol       Date:  2012-09-18       Impact factor: 7.561

Review 8.  The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease.

Authors:  Alberto Altomare; Addolorata Corrado; Nicola Maruotti; Daniela Cici; Francesco Paolo Cantatore
Journal:  Mol Biol Rep       Date:  2021-06-01       Impact factor: 2.316

9.  Characterization of new bone formation in gout: a quantitative site-by-site analysis using plain radiography and computed tomography.

Authors:  Nicola Dalbeth; Aaron Milligan; Anthony J Doyle; Barnaby Clark; Fiona M McQueen
Journal:  Arthritis Res Ther       Date:  2012-07-13       Impact factor: 5.156

Review 10.  How crystals damage tissue.

Authors:  Eamonn S Molloy; Geraldine M McCarthy
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.